

REFERENCES

- Burmeister, T., & Reinhardt, R. (2008). A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts. *Leukemia Research*, 32(4), 579–585. <https://doi.org/10.1016/j.leukres.2007.08.017>
- Đermić, D., Ljubić, S., Matulić, M., Procino, A., Feliciello, M. C., Ugarković, Đ., & Feliciello, I. (2023). Reverse transcription-quantitative PCR (RT-qPCR) without the need for prior removal of DNA. *Scientific reports*, 13(1), 11470. <https://doi.org/10.1038/s41598-023-38383-4>
- Soverini, S., Martinelli, G., Amabile, M., Poerio, A., Bianchini, M., Rosti, G., Pane, F., Saglio, G., & Baccarani, M. (2004). Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to imatinib. *Clinical Chemistry*, 50(7), 1205–1213. <https://doi.org/10.1373/clinchem.2004.031112>
- Morley, A., Bartley, P., Martin-Harris, H., Latham, S., Ross, D., & Hughes, T. (2007). DNA-Based Measurement of BCR-ABL in Chronic Myeloid Leukemia (CML). *Blood*, 110(11), 2946–2946. <https://doi.org/10.1182/blood.v110.11.2946.2946>
- Radich, J. (2018). Is DNA a better assay for residual disease in chronic myeloid leukemia?. *Haematologica*, 103(12), 1942–1944. <https://doi.org/10.3324/haematol.2018.205583>
- Rejali, L., Poopak, B., Hasanzad, M., Sheikhsofla, F., Varnoosfaderani, A. S., Safari, N., & Rabieipoor, S. (2015). Characterizing of four common BCR-ABL kinase domain mutations (T315I, Y253H, M351T and E255K) in Iranian chronic myelogenous leukemia patients with imatinib resistance. *International Journal of Cancer Management*, 8(3). <https://doi.org/10.17795/ijcp2334>
- Eden, R.E., & Coviello, J.M. Chronic Myelogenous Leukemia. [Updated 2023 Jan 16]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK531459/>
- Haider, M.Z., & Anwer, F. Genetics, Philadelphia Chromosome. [Updated 2023 Jul 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK560689/>
- Rajabto, W., Reksodiputro, A. H., Rinaldi, I., Tadjoeidin, H., Priantono, D., & Angkasa, Y. K. (2022). Chronic Myeloid Leukemia (CML) at National Referral Hospital in Indonesia. *Siriraj Medical Journal*, 74(8), 530–536. <https://doi.org/10.33192/Smj.2022.63>

- Mu, H., Zou, J., & Zhang, H. (2024). Quantitative detection of T315I mutations of BCR::ABL1 using digital droplet polymerase chain reaction. *Hematology, Transfusion and Cell Therapy*, 46, S79–S85. <https://doi.org/10.1016/J.HTCT.2023.12.007>
- Sholikah, T. A. (2017). FUSION GENE BCR-ABL : FROM ETIOPATHOGENESIS TO THE MANAGEMENT OF CHRONIC MYELOID LEUKEMIA. *Jurnal Kedokteran Dan Kesehatan Indonesia*, 8(1), 29–37. <https://doi.org/10.20885/jkki.vol8.iss1.art5>
- Wanger, A., Chavez, V., Huang, R. S. P., Wahed, A., Actor, J. K., & Dasgupta, A. (2017). Overview of Molecular Diagnostics Principles. *Microbiology and Molecular Diagnosis in Pathology*, 233–257. <https://doi.org/10.1016/B978-0-12-805351-5.00012-0>
- Nazir, R., Rehman, S., Nisa, M., & Baba, U. Ali. (2019). Exploring bacterial diversity: from cell to sequence. *Freshwater Microbiology: Perspectives of Bacterial Dynamics in Lake Ecosystems*, 263–306. <https://doi.org/10.1016/B978-0-12-817495-1.00007-4>
- Soverini, S., Bernardi, S., & Galimberti, S. (2020). Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?. *Journal of clinical medicine*, 9(12), 3865. <https://doi.org/10.3390/jcm9123865>
- Braun, T. P., Eide, C. A., & Druker, B. J. (2020). Response and Resistance to BCR-ABL1-Targeted Therapies. *Cancer cell*, 37(4), 530–542. <https://doi.org/10.1016/j.ccell.2020.03.006>
- Chaudhary, P., Chaudhary, S., Patel, F., Patel, S., Vaishnani, T., Trivedi, N., Patel, D., Sonagara, T., Hirapara, A., Vyas, K., Patel, L., Kumar, R., Chakraborty, N., Sharma, D., Suthar, J., Kamdar, P., Jajodia, E., Ahmad, F., & Arora, N. (2024). Validation of a novel NGS based BCR::ABL1 kinase domain mutation detection assay in Indian cohort. *Scientific reports*, 14(1), 15745. <https://doi.org/10.1038/s41598-024-66310-8>
- Son, H. J., & Lee, J. H. (2024). Novel Four-Way Variant Translocation, t(1;9;22;16)(q21;q34;q11.2;q24), in a Patient with Chronic Myeloid Leukemia. *Diagnostics (Basel, Switzerland)*, 14(3), 303. <https://doi.org/10.3390/diagnostics14030303>
- Paramita, D. K., Hutajulu, S. H., Syifarahmah, A., Sholika, T. A., Fatmawati, S., Aning, S., Sulistyawati, D., Wahyuni, S., Taroeno-Hariadi, K. W., & Kurnianda, J. (2020). BCR-ABL Gene Transcript Types of Patients with Chronic Myelogenous Leukemia in Yogyakarta, Indonesia. *Asian Pacific journal of cancer prevention : APJCP*, 21(6), 1545–1550. <https://doi.org/10.31557/APJCP.2020.21.6.1545>

- Koçkan, B., Toptaş, T., Atagündüz, I., Tuğlular, A. T., Özer, A., & Akkiprik, M. (2018). Molecular screening and the clinical impacts of BCR-ABL KD mutations in patients with imatinib-resistant chronic myeloid leukemia. *Oncology letters*, 15(2), 2419–2424. <https://doi.org/10.3892/ol.2017.7606>
- Lardo, M., Castro, M., Moiraghi, B., Rojas, F., Borda, N., Rey, J. A., & Lazarowski, A. (2015). MDR1/ABCB1 gene polymorphisms in patients with chronic myeloid leukemia. *Blood research*, 50(3), 154–159. <https://doi.org/10.5045/br.2015.50.3.154>
- Al-Achkar, W., Moassass, F., Youssef, N., & Wafa, A. (2016). Correlation of p210 BCR-ABL transcript variants with clinical, parameters and disease outcome in 45 chronic myeloid leukemia patients. *Journal of B.U.ON. : official journal of the Balkan Union of Oncology*, 21(2), 444–449.